0001855763-23-000005.txt : 20230725 0001855763-23-000005.hdr.sgml : 20230725 20230725143507 ACCESSION NUMBER: 0001855763-23-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230725 FILED AS OF DATE: 20230725 DATE AS OF CHANGE: 20230725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baxter Nicholas W CENTRAL INDEX KEY: 0001312326 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39874 FILM NUMBER: 231108103 MAIL ADDRESS: STREET 1: 220 SPRINGFIELD ROAD STREET 2: ABERDEEN CITY: ABERDEENSHIRE, SCOTLAND STATE: X0 ZIP: AB15 6AU ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexaria Bioscience Corp. CENTRAL INDEX KEY: 0001348362 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202000871 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 BUSINESS PHONE: 250-765-6424 MAIL ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 FORMER COMPANY: FORMER CONFORMED NAME: LEXARIA CORP. DATE OF NAME CHANGE: 20080229 FORMER COMPANY: FORMER CONFORMED NAME: Lexaria Corp. DATE OF NAME CHANGE: 20051229 4 1 primary_doc.xml PRIMARY DOCUMENT X0508 4 2023-07-25 0 0001348362 Lexaria Bioscience Corp. LEXX 0001312326 Baxter Nicholas W 37H KING'S GATE ABERDEEN ABERDEENSHIRE, SCOTLAND X0 AB15 4EL UNITED KINGDOM 1 0 0 0 0 common shares 11000 D Stock Options 3 2021-04-26 2026-04-26 Common Shares 1500 1500 D Stock Options 3 2021-06-08 2026-06-08 Common Shares 5000 6500 D Stock Options 3 2021-09-01 2026-09-01 Common Shares 1900 8400 D Stock Options 3.39 2022-03-08 2027-03-08 Common Shares 3400 11800 D Stock Options 1.96 2022-10-12 2027-10-12 Common Shares 18200 30000 D Stock Options 0.87 2023-07-25 4 A 0 5000 0 A 2023-07-25 2028-07-25 Common Shares 5000 35000 D Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023 Repriced from $6.23 pursuant to shareholder approval received May 9,2023 /Nicholas Baxter/ 2023-07-25